5/11/2023 6:26:23 AM
Takeda FY EPS 204 Yen; Core EPS 558 Yen
4/26/2023 9:09:18 AM
Corza Medical Agrees With Subsidiary Of Takeda To Acquire TachoSil Manufacturing Operations In Linz, Austria
4/11/2023 8:03:38 AM
Takeda Gets FDA Approval To Expand Use Of HYQVIA To Treat Primary Immunodeficiency In Children
4/3/2023 6:28:41 AM
Takeda To Obtain Worldwide Rights To Develop Antibody Drug Conjugates Using Panel Of Selected Antibodies Developed By Innate
3/30/2023 7:03:29 AM
Takeda Publishes Results From Phase 4 Vedolizumab Study In Patients With Chronic Pouchitis In NEJM
2/8/2023 7:26:21 PM
Takeda Completes Acquisition Of Nimbus Therapeutics' TYK2 Program Subsidiary
2/2/2023 2:30:06 AM
Takeda Pharmaceutical 9-month Revenue 2.70 Trln Yen Vs. 3.07 Trln Yen Last Year
1/23/2023 3:04:28 AM
Takeda To Acquire Worldwide (ex-China) License Of HUTCHMED's
Fruquintinib
1/11/2023 8:41:24 AM
Takeda : EXKIVITY Approved In China For Treatment Of Metastatic Non-small Cell Lung Cancer With EGFR
1/9/2023 7:36:08 AM
Arrowhead, Takeda Announce Topline Results From SEQUOIA Phase 2 Study Of Fazirsiran
1/5/2023 6:53:44 AM
Takeda Announces Favorable Phase 3 Safety And Efficacy Results Of TAK-755 As Enzyme Replacement Therapy For CTTP